China approves world's first implantable BCI

Chinas NMPA grants the first regulatory approval for the NEO system, a brain-computer interface helping patients regain movement via neural signals.

China's National Medical Products Administration (NMPA) granted the world's first market approval for an implantable brain-computer interface (BCI) device intended for medical treatment. The device, known as the NEO system, was developed by Neuracle Medical Technology (Shanghai) Co., Ltd., a company incubated by Tsinghua University's Neural Engineering Laboratory.

How the neo system works

The NEO system functions as a high-tech translator for the brain. It uses a minimally invasive extradural implantation technique to place a coin-sized wireless implant on the surface of the dura mater near the motor cortex. The implant records neural signals and transmits them wirelessly to an external processor. For patients aged 18-60 with quadriplegia caused by cervical spinal cord injury who retain some upper-arm function, the system bypasses damaged pathways by converting motor intentions into digital commands that control a pneumatic robotic glove, enabling assisted hand grasping movements.

Bridging laboratory and bedside

This approval marks the first time an implantable BCI has transitioned from clinical trials to a commercially available Class III medical device. Previously confined to research settings, the NEO system has met rigorous NMPA safety and efficacy standards for everyday clinical use. Its epidural design avoids direct penetration of brain tissue, prioritising long-term stability and minimising risks of inflammation or scarring.

The future of neural recovery

The NEO system restores a measure of independence to individuals with severe motor impairments by turning neural signals into functional hand movements. Clinical studies involving 36 procedures showed improvements in grasping function among all participants. As the technology enters routine clinical practice, it opens the door to broader applications in treating neurological disorders and highlights the growing potential of neurotechnology to reconnect the human brain with the physical world.

Key takeaways

On March 13, 2026, China's National Medical Products Administration (NMPA) granted market approval to the NEO implantable BCI system-the world's first for any invasive brain-computer interface medical device.
The system was developed by Neuracle Medical Technology (Shanghai) Co., Ltd., with foundational research from Tsinghua University's Neural Engineering Laboratory.
NEO is a minimally invasive (extradural) implant placed on the dura mater; it does not penetrate brain tissue.
The device is indicated for patients aged 18-60 with quadriplegia due to cervical spinal cord injury who retain partial upper-arm function.
It translates motor cortex signals into commands for a pneumatic robotic glove to assist hand grasping and daily tasks.
This approval represents the first full transition of an implantable BCI from laboratory and trial stages to commercial clinical use.

@sophie

Sophie Laurent

Sophie Laurent is a science communicator and researcher with a deep passion for making complex scientific ideas understandable and exciting for everyone. As a dedicated promoter of scientific knowledge and critical thinking, she bridges the gap between academic research and the general public. Her work spans a wide range of topics - from fundamental physics and biology to emerging technologies - always highlighting the wonder, relevance, and real-world importance of science in our daily lives.

Go to @sophie profile